Spectrofluorimetric and spectrophotometric stability-indicating methods for determination of some oxicams using 7-chloro-4-nitrobenz-2-oxa-1,3-diazole (NBD-Cl).
Two sensitive and selective spectrofluorimetric and spectrophotometric stability-indicating methods have been developed for the determination of some non-steroidal anti-inflammatory oxicam derivatives namely lornoxicam (Lx), tenoxicam (Tx) and meloxicam (Mx) after their complete alkaline hydrolysis. The methods are based on derivatization of alkaline hydrolytic products with 7-chloro-4-nitrobenz-2-oxa-1,3-diazole (NBD-Cl). The products showed an absorption maximum at 460 nm for the three studied drugs and fluorescence emission peak at 535 nm in methanol. The color was stable for at least 48 h. The optimum conditions of the reaction were investigated and it was found that the reaction proceeds quantitatively at pH 8, after heating in a boiling water bath for 30 min. The methods were found to be linear in the ranges of 1-10 microg ml(-1) for Lx and Tx and 0.5-4.0 microg ml(-1) for Mx for spectrophotometric method, while 0.05-1.0 microg ml(-1) for Lx and Tx and 0.025-0.4 microg ml(-1) for Mx for the spectrofluorimetric method. The validity of the methods was assessed according to USP guidelines. Statistical analysis of the results revealed high accuracy and good precision. The suggested procedures could be used for the determination of the above mentioned drugs in pure and dosage forms as well as in the presence of their degradation products.
Taha
Elham Anwer
EA
National Organization for Drug Control and Research, 6 Abou Hazem Street, Pyramids Avenue, Giza, Egypt. dr_elhamtaha@hotmail.com
Salama
Nahla Nour
NN
Fattah
Laila El-Sayed Abdel
Lel-S
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000032:analysis*; D002021:Buffers; D002214:Capsules; D004355:Drug Stability; D006863:Hydrogen-Ion Concentration; D007202:Indicators and Reagents; D000077239:Meloxicam; D009578:Nitrobenzenes / Q000032:analysis*; D010080:Oxazoles / Q000032:analysis*; D019999:Pharmaceutical Solutions; D010894:Piroxicam / Q000031:analogs & derivatives* / Q000032:analysis; D011208:Powders; D015203:Reproducibility of Results; D013050:Spectrometry, Fluorescence; D013056:Spectrophotometry, Ultraviolet; D013607:Tablets; D013843:Thiazines / Q000032:analysis*; D013844:Thiazoles / Q000032:analysis*
C511330:7-chloro-4-nitrobenz-2-oxa-1,3-diazole; D000894:Anti-Inflammatory Agents, Non-Steroidal; D002021:Buffers; D002214:Capsules; D007202:Indicators and Reagents; D009578:Nitrobenzenes; D010080:Oxazoles; D019999:Pharmaceutical Solutions; D011208:Powders; D013607:Tablets; D013843:Thiazines; D013844:Thiazoles; D010894:Piroxicam; C059451:lornoxicam; D000077239:Meloxicam; C032801:tenoxicam